News

The agreement puts in place a number of activities to help progress Metabolon’s Prostarix line of prostate cancer diagnostics including an exclusive license for Metabolon to use prostate

The program was previously the subject of a partnership with GlaxoSmithKline’s cardiovascular centre of excellence for drug discovery unit. Vitae’s other research programs include a substantial collaboration with

Under the agreement, Laureate will produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Robert Broeze, president and

This second study, designed to meet the FDA requirements for US registration, will examine patients between 51 and 80 years old suffering from painful symptoms of knee osteoarthritis.

Further, approximately half of all of the study participants have completed the final observation visit. Isolagen anticipates the acne study will conclude in the first quarter of 2009.

The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California. Patients will be randomized to receive either

The first trial was a 24-week, open-labeled extension to a four-week double-blinded, pivotal trial that enrolled 308 patients. The second trial was a 48-week, open-labeled trial in 250

The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the company plans to initiate

The transaction is subject to regulatory review by competition authorities in the US and Europe, and is expected to complete by early 2009. John Clarke, president of GlaxoSmithKline